 |
|
|
|||||||||||||||
|
|||||||||||||||
| » India | » Asia | » World | » Sports | » Business | » Sci-Tec | » Health | » Entertainment | » Bollywood | » Picture Gallery |
|
India Baxter launches therapy for haemophilia
Chinese pharma major Baxter today launched "Recombinate", a genetically-engineered, non-plasma derived therapy for treatment of Haemophilia, a rare blood disoder, which has been on the rise in the country. Talking to reporters here, Baxter Medical Driector Dr Wing Yen Wong said the launch of the therapy was yet another step in the advancement of haemophilia care in India. This genetically engineered non-plasma derived recombinant factor (rFVIII) through increased viral safety and uninterrupted supply, represents a significant step forward in raising the standards of care for treating haemophilia patients. It was produced from the Chinese hamster Ovary cell line which was time-tested and validated, and was free fro mycoplasma, bacteria, yeast, fungi and viruses. ''It inherently reduces the risk of pathogen transmission'', Ms Yen Wong said. She said Haemophilia was a rare blood disorder in which a person's blood does not clot properly. People living with haemophilia do not have enough or are without one of the blood clotting proteins Factor VIII or Factor IX or Factor XI, naturally found in blood. The body depends on these clotting factors for bleeding to stop after sustaining an injury, to promote clotting. Dr Vikram Mathews of Christian Medical College, Vellore, who was the special guest said people with haemophilia do not bleed more profusely or faster than a normal person. ''But they will bleed for a longer period and internal bleeding usually occurs in joints and muscles, resulting in serious physical consequences and can be life threatening if it occurs in brain or other organs'', he noted. It would be administered through IV fluids directly into the blood stream and would have an effect for 8 to 12 hours. ''Depending on the nature of the injury or in times of surgery, it needs to be continued twice a day till the bleeding stops'', Dr Vikram said. He said there was lack of awareness in India as nearly one lakh people suffer from haemophilia and just 10,000 cases were detected. ''One to two of one lakh new born males in all ethnic groups will have this bleeding disorder'', he said. Haemophilia Federation of India Chennai Region chairman G Parthasarathy said considering that only ten to 12 per cent in India were diagnosed of this disease, the treatment was expensive and it should be covered under the Chief Minister Kalaignar's Health Insurance scheme for life saving treatment. -- (UNI) -- 21MS.xml
Reliance raises $1 billion through overseas bond issue Sensex closes 82 points lower as industrial output slows (Roundup) FIFA urges Uganda football federation to amend constitution Chinese held for poaching panda 17 years ago Anbazhagan blames Pondy govt for rising rate Haryana issues advisory on consumption of Lauki juice Encephalitis not any issue in Poorvanchal during UP polls !
|
|
Quick Links - Webindia123.com
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
